HK Stock MarketDetailed Quotes

09966 ALPHAMAB-B

Watchlist

3.760
-0.140-3.59%

Not Open Dec 4 16:08 CST

3.62BMarket Cap-15284P/E (TTM)

ALPHAMAB-B Stock Forum

Moomoo AI

Feb 7 00:43

Alphamab Oncology's high P/S ratio may not be justified due to weak revenue forecasts. Investors should remain cautious as this could negatively impact the share price.

Alphamab Oncology's (HKG:9966) 31% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Spinee

Jan 17 02:21

HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off

$Hang Seng Index (800000.HK)$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN (09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B (02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH (01873.HK)$ ...

Moomoo AI

Dec 22, 2023 20:10

Due to Alphamab Oncology's slower growth rate compared to the industry and notably high P/S ratio, investors may face potential risks. The company's elevated stock price level may not be sustainable in light of its comparatively weak revenue outlook.

What Alphamab Oncology's (HKG:9966) P/S Is Not Telling You

Flord

Sep 24, 2021 05:26

$ALPHAMAB-B (09966.HK)$ If corning & Jerry's late-stage data can validate the early-stage data, it means that first-line treatment of NSCLC(MOS estimated at more than 25 months in phase II) can obtain MOS data much higher than K

Mikebierer

Sep 24, 2021 05:13

$ALPHAMAB-B (09966.HK)$ $KINTOR PHARMA-B (09939.HK)$ $INNOVENT BIO (01801.HK)$ Today Hong Kong pharmaceutical and biotech stocks fell 2.36%, industry groups in Hong Kong or top 5, kill the biological medicine market valuation, capital is still wary of innovative drug, exploit medicine, corning jerry that is called a fall, but has strong industry leading cinda biology, growth of 4.16% in the pharmaceutical sector in the first, Market money still likes and likes a few big champions.